source
- Agios halts sickle cell drug program after disappointing phase 2 resultsAgios announced it is stopping development of its next‑generation pyruvate kinase activator, tebapivat, for sickle cell disease after a phase 2 trial failed to meet expectations. The study enrolle…
- Biotech firms rally to defend FDA's mifepristone approval in Louisiana lawsuitBiotech companies, executives and investors filed an amicus brief supporting the FDA in the Louisiana case that seeks to limit access to the abortion pill mifepristone. The brief is signed by 61 e…